PD-L1 expression and overall survival in Asian and western patients with gastric cancer

Sun Young Rha; Geoffrey Y. Ku; Hyo Song Kim; Hyun Cheol Chung; Fatemeh Ghazanfari Amlashi; Dipen Maheshbhai Maru; Carly A. Fein; Laura H. Tang; Wei Zhou; Ting Wu; Senaka A. Peter; David P. Kelsen; Jaffer A. Ajani

doi:10.2217/fon-2022-0103

PD-L1 expression and overall survival in Asian and western patients with gastric cancer

Sun Young Rha, Geoffrey Y. Ku, Hyo Song Kim, Hyun Cheol Chung, Fatemeh Ghazanfari Amlashi, Dipen Maheshbhai Maru, Carly A. Fein, Laura H. Tang, Wei Zhou, Ting Wu, Senaka A. Peter, David P. Kelsen, Jaffer A. Ajani

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. Materials & methods: In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Results: Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). Conclusion: PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.

Original language	English
Pages (from-to)	2623-2634
Number of pages	12
Journal	Future Oncology
Volume	18
Issue number	21
DOIs	https://doi.org/10.2217/fon-2022-0103
Publication status	Published - 2022 Jul

Bibliographical note

Funding Information:
SY Rha has served as a consultant and speaker for Eli Lilly and as a consultant for Merck Sharp & Dohme (MSD), Celltrion, and Ipsen and has received research funding from Bristol-Myers Squibb (BMS) and MSD. GY Ku: is a consultant for and has received research funding from Merck & Co., Inc., AstraZeneca, BMS and Pieris; has served as a consultant for Eli Lilly; and has received research funding from Arog Pharma and Aduro Biotech. HC Chung has received honoraria, is a consultant for, and has received research funding from Merck Serono and Eli Lilly; has received honoraria from Foundation Medicine; is a consultant for Taiho, Celltrion, Quintiles, BMS and MSD; and has received research funding from GlaxoSmithKline, BMS-Ono Pharmaceuticals, MSD and Taiho. W Zhou, T Wu and SA Peter are current or former employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA; W Zhou and SA Peter own stock in Merck & Co., Inc., NJ, USA. JA Ajani has received research funding from BMS, Merck & Co. Inc., Astellas, Taiho, DeltaFly, Prolinx, Macrogenics, and Zymeworks and honoraria from BMS, Merck & Co. Inc., Astellas, Taiho, Zymeworks, DAVA/OM, AstraZeneca, Acrotech, and Beigene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Funding Information:
Medical writing and/or editorial assistance was provided by T Stuve and J Burke of the ApotheCom pembrolizumab team (PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA.

Publisher Copyright:
© 2022 Future Medicine Ltd.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2022-0103

Cite this

@article{228a674ef18d44ad8a722546e6b47067,

title = "PD-L1 expression and overall survival in Asian and western patients with gastric cancer",

abstract = "Aim: Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. Materials & methods: In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Results: Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). Conclusion: PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.",

author = "Rha, {Sun Young} and Ku, {Geoffrey Y.} and Kim, {Hyo Song} and Chung, {Hyun Cheol} and Amlashi, {Fatemeh Ghazanfari} and Maru, {Dipen Maheshbhai} and Fein, {Carly A.} and Tang, {Laura H.} and Wei Zhou and Ting Wu and Peter, {Senaka A.} and Kelsen, {David P.} and Ajani, {Jaffer A.}",

note = "Funding Information: SY Rha has served as a consultant and speaker for Eli Lilly and as a consultant for Merck Sharp & Dohme (MSD), Celltrion, and Ipsen and has received research funding from Bristol-Myers Squibb (BMS) and MSD. GY Ku: is a consultant for and has received research funding from Merck & Co., Inc., AstraZeneca, BMS and Pieris; has served as a consultant for Eli Lilly; and has received research funding from Arog Pharma and Aduro Biotech. HC Chung has received honoraria, is a consultant for, and has received research funding from Merck Serono and Eli Lilly; has received honoraria from Foundation Medicine; is a consultant for Taiho, Celltrion, Quintiles, BMS and MSD; and has received research funding from GlaxoSmithKline, BMS-Ono Pharmaceuticals, MSD and Taiho. W Zhou, T Wu and SA Peter are current or former employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA; W Zhou and SA Peter own stock in Merck & Co., Inc., NJ, USA. JA Ajani has received research funding from BMS, Merck & Co. Inc., Astellas, Taiho, DeltaFly, Prolinx, Macrogenics, and Zymeworks and honoraria from BMS, Merck & Co. Inc., Astellas, Taiho, Zymeworks, DAVA/OM, AstraZeneca, Acrotech, and Beigene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: Medical writing and/or editorial assistance was provided by T Stuve and J Burke of the ApotheCom pembrolizumab team (PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA. Publisher Copyright: {\textcopyright} 2022 Future Medicine Ltd.",

year = "2022",

month = jul,

doi = "10.2217/fon-2022-0103",

language = "English",

volume = "18",

pages = "2623--2634",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "21",

}

TY - JOUR

T1 - PD-L1 expression and overall survival in Asian and western patients with gastric cancer

AU - Rha, Sun Young

AU - Ku, Geoffrey Y.

AU - Kim, Hyo Song

AU - Chung, Hyun Cheol

AU - Amlashi, Fatemeh Ghazanfari

AU - Maru, Dipen Maheshbhai

AU - Fein, Carly A.

AU - Tang, Laura H.

AU - Zhou, Wei

AU - Wu, Ting

AU - Peter, Senaka A.

AU - Kelsen, David P.

AU - Ajani, Jaffer A.

N1 - Funding Information: SY Rha has served as a consultant and speaker for Eli Lilly and as a consultant for Merck Sharp & Dohme (MSD), Celltrion, and Ipsen and has received research funding from Bristol-Myers Squibb (BMS) and MSD. GY Ku: is a consultant for and has received research funding from Merck & Co., Inc., AstraZeneca, BMS and Pieris; has served as a consultant for Eli Lilly; and has received research funding from Arog Pharma and Aduro Biotech. HC Chung has received honoraria, is a consultant for, and has received research funding from Merck Serono and Eli Lilly; has received honoraria from Foundation Medicine; is a consultant for Taiho, Celltrion, Quintiles, BMS and MSD; and has received research funding from GlaxoSmithKline, BMS-Ono Pharmaceuticals, MSD and Taiho. W Zhou, T Wu and SA Peter are current or former employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA; W Zhou and SA Peter own stock in Merck & Co., Inc., NJ, USA. JA Ajani has received research funding from BMS, Merck & Co. Inc., Astellas, Taiho, DeltaFly, Prolinx, Macrogenics, and Zymeworks and honoraria from BMS, Merck & Co. Inc., Astellas, Taiho, Zymeworks, DAVA/OM, AstraZeneca, Acrotech, and Beigene. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: Medical writing and/or editorial assistance was provided by T Stuve and J Burke of the ApotheCom pembrolizumab team (PA, USA). This assistance was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., NJ, USA. Publisher Copyright: © 2022 Future Medicine Ltd.

PY - 2022/7

Y1 - 2022/7

N2 - Aim: Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. Materials & methods: In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Results: Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). Conclusion: PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.

AB - Aim: Data are limited on PD-L1 expression and its association with overall survival (OS) in gastric cancer (GC) patients receiving routine care in different regions. Materials & methods: In a retrospective study, PD-L1 expression was assayed using the 22C3 pharmDx on GC tumor samples collected between 2003 and 2017 at South Korean and US cancer centers. PD-L1 positivity was defined as combined positive score (CPS) ≥1. The relationship between PD-L1 and OS was analyzed. Results: Of 574 GC tumor samples, 67.4% were CPS ≥1 (68.7% in Korean and 65.7% in US patients). PD-L1 expression was not associated with OS (adjusted hazard ratio: 0.94; 95% CI: 0.75-1.17). Conclusion: PD-L1 prevalence and its association with OS was similar between South Korean and US GC patients.

UR - http://www.scopus.com/inward/record.url?scp=85132245799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85132245799&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0103

DO - 10.2217/fon-2022-0103

M3 - Article

C2 - 35616013

AN - SCOPUS:85132245799

SN - 1479-6694

VL - 18

SP - 2623

EP - 2634

JO - Future Oncology

JF - Future Oncology

IS - 21

ER -

PD-L1 expression and overall survival in Asian and western patients with gastric cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this